Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Malignant pleural mesothelioma multidisciplinary team unit: experience of one high-volume center in Italy.

Gianoncelli L, Nava V, Mazza L, Bonomi M, Cerchiaro E, Zanello A, De Filippis CN, Mazzoleni M, Vernile L, Ruello A, Vargas J, Beretta G, Bortolotti L, Vavassori V, Maggioni P, Ceresoli GL.

Ann Oncol. 2017 Oct;28 Suppl 6:vi63. doi: 10.1093/annonc/mdx426.029. No abstract available.

PMID:
31962782
2.

Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM).

Grosso F, Ceresoli GL, Roveta A, Bearz A, Valentino F, Novello S, Santoro A, Cognetti F, Amadori D, Dall'olio FG, Zucchi L, Pastorino U, Rea F, Boni C, Maggioni P, Gallizzi G, Maconi A, Scagliotti GV, Magnani C.

Ann Oncol. 2017 Oct;28 Suppl 6:vi59. doi: 10.1093/annonc/mdx426.016. No abstract available.

PMID:
31962763
3.

Maintenance treatment with bevacizumab in metastatic colorectal cancer: intermittent or continuous therapy? A monoinstitutional observational study.

Cerchiaro E, Squadroni M, Brena F, Sauta MG, Bonomi M, Ripa C, Barile R, Salvini P, Ceresoli GL, Beretta G.

Ann Oncol. 2017 Oct;28 Suppl 6:vi12. doi: 10.1093/annonc/mdx422.030. No abstract available.

PMID:
31962601
4.

Tumour Treating Fields for mesothelioma - Authors' reply.

Ceresoli GL, Gianoncelli L, Grosso F; STELLAR investigators.

Lancet Oncol. 2020 Jan;21(1):e10. doi: 10.1016/S1470-2045(19)30831-9. No abstract available.

PMID:
31908296
5.

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

Reale ML, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D, Ceresoli GL, Finocchiaro G, Romano GD, Piovano PL, Del Conte A, Borra G, Verderame F, Scotti V, Nonnis D, Galetta D, Sergi C, Migliorino MR, Tonini G, Cecere F, Berardi R, Pino MS, Martelli O, Gelibter A, Carta A, Vattemi E, Pagano M, Zullo A, Ferrari S, Rossi A, Novello S.

Lung Cancer. 2020 Feb;140:71-79. doi: 10.1016/j.lungcan.2019.12.006. Epub 2019 Dec 16.

PMID:
31884129
6.

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.

Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D.

Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20.

PMID:
31881412
7.

Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.

Rossi S, Finocchiaro G, Noia VD, Bonomi M, Cerchiaro E, Rose F, Franceschini D, Navarria P, Ceresoli GL, Beretta GD, D'Argento E, Scorsetti M, Santoro A, Toschi L.

Future Oncol. 2019 Nov;15(33):3775-3782. doi: 10.2217/fon-2019-0349. Epub 2019 Nov 11.

PMID:
31709807
8.

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.

Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F.

Lancet Oncol. 2019 Dec;20(12):1702-1709. doi: 10.1016/S1470-2045(19)30532-7. Epub 2019 Oct 15.

PMID:
31628016
9.

Approved and emerging treatments of malignant pleural mesothelioma in elderly patients.

Ceresoli GL, Rossi A.

Expert Rev Respir Med. 2019 Dec;13(12):1179-1188. doi: 10.1080/17476348.2019.1678386. Epub 2019 Oct 16.

PMID:
31596154
10.

In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.

Lopci E, Novellis P, Testori A, Rahal D, Voulaz E, Bottoni E, Ferraroli GM, Crepaldi A, Ceresoli GL, Perrino M, Castello A, Alloisio M, Veronesi G, Zucali PA.

Nucl Med Commun. 2019 Nov;40(11):1179-1186. doi: 10.1097/MNM.0000000000001078.

PMID:
31568271
11.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
12.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15.

PMID:
31103412
13.

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.

Rossi S, Toschi L, Finocchiaro G, Di Noia V, Bonomi M, Cerchiaro E, Ceresoli GL, Beretta GD, D'Argento E, Santoro A.

Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2.

PMID:
30473385
14.

Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.

Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.

J Thorac Oncol. 2018 Aug;13(8):1146-1155. doi: 10.1016/j.jtho.2018.04.025. Epub 2018 May 3.

15.

Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.

Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.

Ann Oncol. 2018 May 1;29(5):1258-1265. doi: 10.1093/annonc/mdy086.

PMID:
29514216
16.

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study.

Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, Bombardieri E.

Cancer Manag Res. 2017 Dec 7;9:789-800. doi: 10.2147/CMAR.S148323. eCollection 2017. Erratum in: Cancer Manag Res. 2018 Mar 27;10 :613.

17.

Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.

Cancer Med. 2017 Oct;6(10):2287-2296. doi: 10.1002/cam4.1182. Epub 2017 Sep 21.

18.

Clinical staging of malignant pleural mesothelioma: current perspectives.

Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL.

Lung Cancer (Auckl). 2017 Aug 18;8:127-139. doi: 10.2147/LCTT.S102113. eCollection 2017. Review.

19.

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

Calabrò L, Ceresoli GL, D'Incecco A, Scherpereel A, Aerts J, Maio M.

Cytokine Growth Factor Rev. 2017 Aug;36:25-31. doi: 10.1016/j.cytogfr.2017.07.003. Epub 2017 Jul 12. Review.

PMID:
28736182
20.

Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.

Meriggi F, Codignola C, Beretta GD, Ceresoli GL, Caprioli A, Scartozzi M, Fraccon AP, Prochilo T, Ogliosi C, Zaniboni A.

Tumori. 2017 Sep 18;103(5):443-448. doi: 10.5301/tj.5000632. Epub 2017 Jul 14.

PMID:
28731495
21.

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).

Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C.

BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3.

22.

Immune checkpoint inhibitors in malignant pleural mesothelioma.

Ceresoli GL, Mantovani A.

Lancet Oncol. 2017 May;18(5):559-561. doi: 10.1016/S1470-2045(17)30191-2. No abstract available.

PMID:
28495276
23.

Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.

Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli GL, Soto Parra HJ, Auriati L, Simonassi C.

Oncol Res Treat. 2017;40(6):364-369. doi: 10.1159/000464410. Epub 2017 May 9. Review.

PMID:
28472807
24.

Radiotherapy to intervention sites in mesothelioma: no more?

Ceresoli GL, Vavassori V.

Lancet Oncol. 2016 Aug;17(8):1025-1027. doi: 10.1016/S1470-2045(16)30132-2. Epub 2016 Jun 23. No abstract available.

25.

Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.

Ceresoli GL, Bonomi M, Sauta MG.

Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5. doi: 10.1080/14737140.2016.1191951. Epub 2016 May 30. No abstract available.

PMID:
27224058
26.

MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.

Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte P, Calabrese F.

Oncotarget. 2015 Dec 8;6(39):42053-66. doi: 10.18632/oncotarget.5974.

27.

Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.

Ceresoli GL, Zucali PA.

Cancer Treat Rev. 2015 Dec;41(10):853-8. doi: 10.1016/j.ctrv.2015.10.006. Epub 2015 Oct 28. Review.

PMID:
26526504
28.

Role of of Nuclear Medicine in the multidisciplinary management of prostate cancer.

Ceresoli GL, Bombardieri E.

Q J Nucl Med Mol Imaging. 2015 Dec;59(4):357-8. No abstract available.

PMID:
26416035
29.

Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment.

Bombardieri E, Evangelista L, Ceresoli GL, Boccardo F.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):5-7. doi: 10.1007/s00259-015-3189-0. Epub 2015 Sep 18. No abstract available.

PMID:
26381776
30.

Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.

Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.

Q J Nucl Med Mol Imaging. 2015 Dec;59(4):400-10. Epub 2015 Sep 3. Review.

PMID:
26337241
31.

Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.

Ceresoli GL, De Vincenzo F, Sauta MG, Bonomi M, Zucali PA.

Q J Nucl Med Mol Imaging. 2015 Dec;59(4):374-80. Epub 2015 Jul 29. Review.

PMID:
26222275
32.

Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.

Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75. doi: 10.1007/s00259-014-2960-y. Epub 2014 Nov 18.

PMID:
25403555
33.

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M.

Cancer Immunol Immunother. 2015 Jan;64(1):105-12. doi: 10.1007/s00262-014-1609-9. Epub 2014 Sep 19. Review.

PMID:
25233793
34.

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.

Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M.

Br J Cancer. 2014 Jul 15;111(2):220-6. doi: 10.1038/bjc.2014.312. Epub 2014 Jun 10.

35.

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.

Lung Cancer. 2014 Jun;84(3):265-70. doi: 10.1016/j.lungcan.2013.11.011. Epub 2013 Nov 20.

PMID:
24321581
36.

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises.

Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM, Wannesson L.

Curr Pharm Des. 2014;20(24):3982-90. Review.

PMID:
24138721
37.

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A.

Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16.

38.

Adjuvant radiotherapy for malignant pleural mesothelioma: challenges and pitfalls.

Ceresoli GL, Ricardi U, Vavassori V, Scorsetti M.

Radiother Oncol. 2012 Nov;105(2):271. doi: 10.1016/j.radonc.2012.04.026. Epub 2012 Nov 3. No abstract available.

PMID:
23127769
39.

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA.

Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15.

PMID:
22704893
40.

Anti-angiogenic therapies for malignant pleural mesothelioma.

Ceresoli GL, Zucali PA.

Expert Opin Investig Drugs. 2012 Jun;21(6):833-44. doi: 10.1517/13543784.2012.681641. Epub 2012 Apr 23. Review.

PMID:
22519641
41.

An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

Pasello G, Ceresoli GL, Favaretto A.

Cancer Treat Rev. 2013 Feb;39(1):10-7. doi: 10.1016/j.ctrv.2012.03.001. Epub 2012 Mar 27. Review.

PMID:
22459200
42.

FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy.

Ceresoli GL.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):921-4. doi: 10.1007/s00259-012-2094-z. No abstract available.

PMID:
22426828
43.

Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer.

Ceresoli GL.

Curr Cancer Drug Targets. 2012 Mar;12(3):237-46. Review.

PMID:
22229252
44.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
45.

Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.

De Vincenzo F, Zucali PA, Ceresoli GL, Colombo P, Simonelli M, Lorenzi E, Perrino M, Gianoncelli L, De Sanctis R, Graziotti P, Santoro A.

J Clin Oncol. 2011 Jun 20;29(18):e529-31. doi: 10.1200/JCO.2011.34.8284. Epub 2011 Apr 11. No abstract available.

PMID:
21483010
46.

Advances in the biology of malignant pleural mesothelioma.

Zucali PA, Ceresoli GL, De Vincenzo F, Simonelli M, Lorenzi E, Gianoncelli L, Santoro A.

Cancer Treat Rev. 2011 Nov;37(7):543-58. doi: 10.1016/j.ctrv.2011.01.001. Epub 2011 Feb 1. Review.

PMID:
21288646
47.

Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.

Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A.

Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24.

48.

Prostatic stromal tumor with fatal outcome in a young man: histopathological and immunohistochemical case presentation.

Colombo P, Ceresoli GL, Boiocchi L, Taverna G, Grizzi F, Bertuzzi A, Santoro A, Roncalli M.

Rare Tumors. 2010 Dec 31;2(4):e57. doi: 10.4081/rt.2010.e57.

49.

Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A.

Lung Cancer. 2011 Apr;72(1):73-7. doi: 10.1016/j.lungcan.2010.12.004. Epub 2011 Jan 8.

PMID:
21216487
50.

Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.

Nowak AK, Armato SG 3rd, Ceresoli GL, Yildirim H, Francis RJ.

Lung Cancer. 2010 Oct;70(1):1-6. doi: 10.1016/j.lungcan.2010.05.016. Epub 2010 Jun 11. Review.

PMID:
20541834

Supplemental Content

Loading ...
Support Center